TGFBR1 (Transforming Growth Factor Beta Receptor 1) is a serine/threonine kinase receptor that plays a critical role in mediating signals from the TGF-β superfamily, regulating cell proliferation, differentiation, apoptosis, and immune responses. Dysregulation of TGFBR1 is implicated in various diseases, including cancer, fibrosis, and cardiovascular disorders. Antibodies targeting TGFBR1 are essential tools for studying its expression, activation, and downstream signaling pathways. These antibodies are widely used in research applications such as Western blotting, immunohistochemistry, and flow cytometry to detect receptor levels or phosphorylation status in cellular and tissue samples. Additionally, TGFBR1-targeting therapeutic antibodies or inhibitors are under investigation for diseases where TGF-β signaling is hyperactive, such as metastatic cancers or fibrotic conditions. Some studies also explore TGFBR1 mutations (e.g., in hereditary hemorrhagic telangiectasia) and its role in drug resistance. However, challenges remain in balancing therapeutic efficacy with potential side effects, given TGF-β's dual tumor-suppressive and pro-oncogenic roles. Overall, TGFBR1 antibodies serve as both research reagents and potential clinical agents, reflecting their versatility in understanding and modulating TGF-β pathway biology.